Select Your Region
Global
A study of ocrelizumab in patients with multiple sclerosis (MuSicalE)
Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis (MuSicalE)
- Autoimmune Disorder
- Multiple Sclerosis (MS)
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:
Active, not recruiting
This trial runs in
Cities
- A Coruña
- Alexandria Governorate
- Amstetten
- Ancona
- Ankara
- Badalona
- Bahia
- Barcelona
- Bari
- Belfast
- Beograd
- Białystok
- Bogotá
- Bonheiden
- Brasschaat
- Bratislavský kraj
- Breda
- Bristol
- Bruxelles
- București
- Cagliari
- Cairo Governorate
- Cali
- Cartagena
- Casarano
- Catania
- Charleroi
- Cluj-Napoca
- Coppito
- Coventry
- Cádiz
- Córdoba
- Distrito Federal
- Doha
- Donostia
- Dubai
- Edegem
- El Palmar
- Elche
- emilia-romagna
- figueres
- Gallarate
- gasteiz
- Gdańsk
- Genova
- Hasselt
- Innsbruck
- Inverness
- İstanbul
- İzmir
- Jette
- Katowice
- Kocaeli
- Kortrijk
- Kragujevac
- Krasnodar
- La Laguna
- La Louvière
- Lazio
- Leeds
- Lincoln
- Linz
- Lisboa
- Lombardia
- London
- luik
- Luton
- Martin
- Melk
- Mersin
- Middlesbrough
- Milano
- Mondovì
- Moscow
- Málaga
- Napoli
- Nieuwegein
- Niš
- Novi Sad
- Novosibirsk
- Oostende
- Oxford
- Palermo
- Panama City
- Paraná
- Parma
- Pavia
- Pelt
- Pleven
- Plovdiv
- Plymouth
- Podgorica
- Pozzilli
- Rio de Janeiro
- Roeselare
- Roma
- Rotterdam
- Rudna Mała
- Rybnik
- Sabadell
- Saint Petersburg
- Samsun
- Santa Cruz de Tenerife
- Santiago de Compostela
- Santo Domingo
- Sevilla
- Sheffield
- Sibiu
- Siena
- Sofia
- Steenokkerzeel
- Stoke-on-Trent
- Sunderland
- Swansea
- São Paulo
- tinlot
- Trabzon
- Trnavský kraj
- Târgu Mureș
- València
- Varna
- Venlo
- Vigo
- Warszawa
- Wien
- Yvoir
- Zabrze
- Zwolle
- Ávila
- Łódź
- Žilinský kraj
- София
- أبو ظبي
Trial Identifier:
NCT03593590 MN39889
Trial Summary
This is a multicentre non-interventional study aimed at evaluating the real-world effectiveness and safety of ocrelizumab treatment in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS), who have been prescribed ocrelizumab as per routine practice. This study will use a comprehensive combination of participant reported outcomes and conventional multiple sclerosis (MS) endpoints that measure clinical domains commonly affected by MS (e.g. fatigue, hand function, gait, cognition), and their impact on employment, activities of daily living, quality of life and healthcare resource utilization. The incidence, type, and pattern of serious adverse events (SAEs), and of adverse events (AEs) leading to treatment discontinuation will also be determined.
Hoffmann-La Roche
Sponsor
N/A
Phase
NCT03593590, MN39889
Trial Identifier
All
Gender
≥ 18 Years
Age
No
Healthy Volunteers
How does the MuSicalE study work?
This study is recruiting people who have different types of multiple sclerosis. The study will include patients whose doctor has decided to prescribe a treatment called ocrelizumab for their multiple sclerosis.
How do I take part in this study?
To be able to take part in this study, your doctor must have decided to prescribe ocrelizumab for your multiple sclerosis, and you must not have received ocrelizumab before.
If your doctor thinks that you might be able to take part in this study, he/she will give you all the information you need to make your decision about taking part in the study.
What treatment will I be given if I join this study?
Everyone who joins this study will receive ocrelizumab.
- Ocrelizumab will be given into your vein (called an intravenous infusion), first as two separate doses given 2 weeks apart, and then once every 6 months for at least 4 years.
If your doctor recommends that you are treated with ocrelizumab, you will still receive this treatment even if you decide not to take part in this study.
How often will I be seen in follow-up appointments, and for how long?
In this study, you will be given ocrelizumab every 6 months for 4 years. You will be followed up for assessment of the effectiveness and safety of ocrelizumab depending on the guidelines for your local area. Some of the assessments require you to answer questionnaires, at home or in the hospital, before your ocrelizumab infusion. You are free to stop this treatment at any time.
Your care and treatment will be determined by your doctor, and information for this study will be collected from assessments and tests that your doctor carries out at each visit, which will be scheduled once every 6 months.
What happens if I’m unable to take part in this study?
If your specific type of multiple sclerosis does not match what this study is looking at or you have previously received ocrelizumab you will not be able to take part in this study. You will still be able to receive ocrelizumab as prescribed by your doctor. You will not lose access to any of your regular care.
For more information about this study see the For Expert tab on this page or follow this link to ClinicalTrials.gov
Trial-identifier: NCT03593590
Trial Summary
This is a multicentre non-interventional study aimed at evaluating the real-world effectiveness and safety of ocrelizumab treatment in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS), who have been prescribed ocrelizumab as per routine practice. This study will use a comprehensive combination of participant reported outcomes and conventional multiple sclerosis (MS) endpoints that measure clinical domains commonly affected by MS (e.g. fatigue, hand function, gait, cognition), and their impact on employment, activities of daily living, quality of life and healthcare resource utilization. The incidence, type, and pattern of serious adverse events (SAEs), and of adverse events (AEs) leading to treatment discontinuation will also be determined.
Hoffmann-La Roche
Sponsor
N/A
Phase
NCT03593590, MN39889
Trial Identifier
Ocrelizumab
Treatments
Multiple Sclerosis
Condition
Official Title
A Multicentre Non-interventional Study to Assess the Real-world Effectiveness of Ocrelizumab in Patients With Relapsing or Primary Progressive Multiple Sclerosis - The MuSicalE STUDY
Eligibility Criteria
All
Gender
≥ 18 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Must have a definite diagnosis of RMS or PPMS and in whom a decision to initiate ocrelizumab has been taken as part of routine clinical practice
- Must be prescribed ocrelizumab in line with the SmPC
- Must have provided signed informed consent
- Must be able and willing to complete the PROs as per clinical practice
Exclusion Criteria
- Previously treated with ocrelizumab (including phase II, phase III and phase IIIB clinical trials, local trials and investigator initiated study (IIS) as well as a pre-approval access or compassionate use programmes or local registries that are not compatible with the MuSicalE study design)
- Not receiving ocrelizumab in line with the SmPC
For the latest version of this information please go to www.forpatients.roche.com